<DOC>
	<DOCNO>NCT00279045</DOCNO>
	<brief_summary>The study compare evaluate effect long-term treatment monotherapy rosiglitazone , metformin glyburide/glibenclamide improvement maintenance glycemic control patient recently diagnose type 2 diabetes mellitus .</brief_summary>
	<brief_title>Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>Inclusion criterion : Newly diagnose patient ( &lt; 3years ) type 2 diabetes . Fasting plasma glucose ( FPG ) range 126240 mg/dL Screening . No previous treatment oral parenteral glucoselowering therapy . Exclusion criterion : History lactic acidosis . Anemia ( &lt; 11g male , &lt; 10 g female ) . Unstable severe NY Heart Associationclass 3 4 . Any NY Heart Association congestive heart failure . Patients chronic disease require periodic intermittent treatment oral intravenous corticosteroid .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>type 2 diabetes monotherapy treatment naive</keyword>
</DOC>